Key statistics
On Friday, Genfit SA (GNFT:NSQ) closed at 5.23, -18.57% below its 52-week high of 6.42, set on Oct 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.52 |
---|---|
High | 5.52 |
Low | 5.10 |
Bid | 4.39 |
Offer | 6.51 |
Previous close | 5.71 |
Average volume | 6.72k |
---|---|
Shares outstanding | 49.94m |
Free float | 43.32m |
P/E (TTM) | -- |
Market cap | 263.84m USD |
EPS (TTM) | -0.6231 USD |
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Announcements
- GENFIT : Information financière du troisième trimestre 2024
- GENFIT Reports Third Quarter 2024 Financial Information
- GENFIT : Iqirvo® d’Ipsen (elafibranor) reçoit l’approbation UE en tant que traitement first-in-class de la Cholangite Biliaire Primitive consécutivement à l’approbation accélérée de la FDA américaine
- GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval
- GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update
- GENFIT : Résultats financiers du premier semestre 2024 et point sur les activités de la Société
- GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis
- GENFIT : Avis positif du Comité des médicaments à usage humain (CHMP) pour l’Iqirvo® (élafibranor) d’Ipsen dans la Cholangite Biliaire Primitive
- GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial
- GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
More ▼